Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Writing IMRAD introduction, methods, results, discussion

2nd ecancer – TMC Kolkata Oncology Congress

30 Sep - 1 Oct 2023

Published: 10 Oct 2023

Views: 75

Rating:

Save

Dr Soumitra S Datta - TMC, Kolkata

Dr Soumitra S Datta speaks at the 2nd ecancer TMC Oncology Congress, which was held at the Tata Medical Center, Kolkata, on 31 September and 1 October 2023.

Related Videos

Patient advocacy – the right communication

Dr Geeta Kadayaprath - Max Super Speciality Hospital, Delhi, India

Patient advocacy – the right communication ( Dr Geeta Kadayaprath - Max Super Speciality Hospital, Delhi, India )

The enhancing oncology model and other value-based propositions

Dr Kelly King - Memorial Healthcare System, Florida, USA

The enhancing oncology model and other value-based propositions ( Dr Kelly King - Memorial Healthcare System, Florida, USA )

Advocacy that impacts patients outcomes in Africa - challenges and opportunities

Franklin Mtei - Patient Advocate, Inspire2Live

Advocacy that impacts patients outcomes in Africa - challenges and opportunities ( Franklin Mtei - Patient Advocate, Inspire2Live )

Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally...

Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium

Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally advanced head and neck squamous cell carcinoma ( Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium )

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan

Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston...

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan ( Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston, USA )

Updated data from the Phase 1/2 MajesTEC-1 study evaluating teclistamab, a BCMA...

Dr Ajay Nooka - Winship Cancer Institute of Emory University, Georgia, USA

Updated data from the Phase 1/2 MajesTEC-1 study evaluating teclistamab, a BCMA x CD3 bispecific antibody ( Dr Ajay Nooka - Winship Cancer Institute of Emory University, Georgia, USA )

CheckMate 9ER: aRCC patients on nivolumab plus cabozantinib achieved deeper...

Dr Cristina Suarez - Vall d’Hebron University Hospital, Catalonia, Spain

CheckMate 9ER: aRCC patients on nivolumab plus cabozantinib achieved deeper responses vs sunitinib ( Dr Cristina Suarez - Vall d’Hebron University Hospital, Catalonia, Spain )

COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity...

Dr Sumanta K. Pal - City of Hope Comprehensive Cancer Center, Duarte, USA

COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity in inoperable locally advanced/metastatic urothelial carcinoma ( Dr Sumanta K. Pal - City of Hope Comprehensive Cancer Center, Duarte, USA )

Latest in testing and diagnostics in exon 20 NSCLC

Dr Antonio Passaro and Prof Paul Hofman

Latest in testing and diagnostics in exon 20 NSCLC ( Dr Antonio Passaro and Prof Paul Hofman )

More from ecancer